MetaX IPO Soars as China’s AI Chip Stocks Ignite Investor Frenzy 
Amazon in Talks to Invest $10 Billion in OpenAI as AI Firm Eyes $1 Trillion IPO Valuation 
Ford Takes $19.5 Billion Charge as EV Strategy Shifts Toward Hybrids 
HSBC’s $13.6 Billion Take-Private Offer for Hang Seng Bank Gains Board Backing 
Blackstone Leads $400 Million Funding Round in Cyera at $9 Billion Valuation 
Trump Sues BBC for Defamation Over Edited Capitol Riot Speech Clip 
Coca-Cola’s Proposed Sale of Costa Coffee Faces Uncertainty Amid Price Dispute 
Fortescue Expands Copper Portfolio With Full Takeover of Alta Copper 
SpaceX Begins IPO Preparations as Wall Street Banks Line Up for Advisory Roles 
Korea Zinc to Build $7.4 Billion Critical Minerals Refinery in Tennessee With U.S. Government Backing 
Nomura Expands Alternative Assets Strategy With Focus on Private Debt Acquisitions 
Apple Explores India for iPhone Chip Assembly as Manufacturing Push Accelerates 
Robinhood Expands Sports Event Contracts With Player Performance Wagers 
California Jury Awards $40 Million in Johnson & Johnson Talc Cancer Lawsuit 
Woolworths Faces Fresh Class Action Over Alleged Underpayments, Shares Slide 
Strategy Retains Nasdaq 100 Spot Amid Growing Scrutiny of Bitcoin Treasury Model 
Treasury Wine Estates Shares Plunge on Earnings Warning Amid U.S. and China Weakness 
GAITHERSBURG, Md., Nov. 02, 2016 -- Novavax, Inc. (Nasdaq:NVAX) today announced it will host an Investor and Analyst update as part of its third quarter financial results conference call and webcast after the close of U.S. financial markets on Wednesday, November 9, 2016.
Management will host a conference call to discuss the quarterly financial results and provide an update on corporate activities. Please be sure to join the webcast in order to access the slide presentation.
Conference call details are as follows:
| Date: | Wednesday, November 9, 2016 |
| Time: | 4:30 p.m. U.S. Eastern Time (ET) |
| Dial-in number: | (877) 212-6076 (Domestic) or (707) 287-9331 (International) |
| Passcode: | 10126707 |
| Webcast: | www.novavax.com, “Investors”/ “Events” |
Conference call replay:
| Dates: | Starting at 7:30 p.m. ET, August 9, 2016 until August 16, 2016 |
| Dial-in number: | (855) 859-2056 (Domestic) or (404) 537-3406 (International) |
| Passcode: | 10126707 |
| Webcast: | www.novavax.com, “Investors”/ “Events” |
About Novavax
Novavax, Inc. (Nasdaq:NVAX) is a clinical-stage vaccine company committed to delivering novel products to prevent a broad range of infectious diseases. Its recombinant nanoparticles and Matrix-M™ adjuvant technology are the foundation for groundbreaking innovation that improves global health through safe and effective vaccines.
Contact: Novavax, Inc. Barclay A. Phillips SVP, Chief Financial Officer and Treasurer Andrea N. Flynn, Ph.D. Associate Director, Investor Relations [email protected] 240-268-2000
